Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -376.00% | -39.59% | 68.38% | -110.06% | 22.19% |
| Total Depreciation and Amortization | -3.50% | 3.63% | -9.07% | 31.41% | 1.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,589.66% | 198.81% | -95.01% | 728.64% | 8.84% |
| Change in Net Operating Assets | -826.01% | 84.07% | -118.17% | 459.86% | -81.78% |
| Cash from Operations | 4.36% | 7.03% | -241.38% | 149.56% | 13.62% |
| Capital Expenditure | -100.00% | 101.23% | -68.90% | -14.31% | 74.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 93.90% | -300.00% |
| Cash from Investing | -7,370.83% | 101.23% | -64.56% | 21.52% | 62.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28,046.20% | 900.00% | -99.88% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 21.14% | 70.71% | -766.67% | 280.00% | 94.25% |
| Cash from Financing | 37,203.45% | 201.89% | -100.89% | 40,553.40% | -100.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 749.85% | 25.00% | -145.65% | 267.77% | -5.07% |